Heart Failure Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast Year, 2025-2035

June 2025 | - | ID: H5E5DF6C6074EN
BIS Research Inc.

Abstracts

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

This report will be delivered in 7-10 working days.Market Lifecycle Stage

The global heart failure market is currently in the expansion phase, with increasing adoption of new therapies and technological advancements. The rising number of heart failure patients globally, alongside advancements in drug development and medical devices, is fuelling market growth. The introduction of personalized treatments and devices that enhance heart function is expected t%li%continue propelling the market forward.

Impact

Technological advancements in drug development, cardiac devices, and patient monitoring systems are significantly impacting the global heart failure market. The development of novel heart failure treatments and wearable devices is improving patient outcomes and enabling better management of heart failure symptoms, especially in chronic and severe cases.

Market Segmentation-

Segmentation 1: By Drug Class

• ACE Inhibitors
• Beta Blockers
• Diuretics
• Angiotensin 2 Receptor Antagonists
• Aldosterone Antagonists
• Others

The market is largely driven by ACE inhibitors and beta blockers, which are commonly used t%li%manage blood pressure and heart function. Diuretics are a significant segment, often used t%li%reduce fluid retention in heart failure patients. Newer drug classes such as Angiotensin 2 receptor antagonists are gaining traction as alternatives for patients wh%li%cannot tolerate ACE inhibitors.

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

The market is dominated by North America, with the U.S. leading the market, driven by advanced healthcare systems and a high prevalence of cardiovascular diseases. Europe and Asia-Pacific are als%li%significant markets, with Europe benefiting from strong healthcare infrastructure and Asia-Pacific seeing rapid growth due t%li%increasing healthcare access and rising heart failure incidences.

Demand – Drivers and Limitations

Demand Drivers for the Global Heart Failure Market:

• Increasing prevalence of heart failure, especially among the aging population
• Advancements in drug development and medical devices for heart failure
• Growing demand for personalized treatments
• Rising awareness and availability of healthcare services

Limitations for the Global Heart Failure Market:

• High costs associated with advanced heart failure treatments and devices
• Complexity in the diagnosis and treatment of heart failure

How can this report add value t%li%an organization?

Product/Innovation: The report provides an in-depth analysis of various drug classes and therapeutic products, helping organizations understand the evolving landscape of heart failure treatments. It outlines how companies can leverage new treatment modalities and technologies t%li%innovate and improve patient outcomes.

Growth/Marketing: With the increasing demand for heart failure treatments, companies are focusing on expanding their market presence. The report offers strategies for business growth, including opportunities in underserved markets and leveraging new therapies t%li%enhance marketing efforts.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players such as Novartis, and Pfizer. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global heart failure market.

Key Market Players and Competition Synopsis

The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global heart failure market. Leading players in the global heart failure market include:

• Novartis AG
• Pfizer Inc.
• Bayer AG

Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria

1. GLOBAL HEART FAILURE: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem
1.2 Market Trends
1.3 Epidemiological Analysis of Heart Failure
  1.3.1 U.S.
  1.3.2 EU5
  1.3.3 Rest-of-the-World
1.4 Clinical Trials
1.5 Regulatory Landscape Analysis
  1.5.1 Legal Requirement and Framework in U.S.
  1.5.2 Legal Requirement and Framework in E.U.
  1.5.3 Legal Requirement and Framework in Asia-Pacific
  1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.6 Market Dynamics
  1.6.1 Impact Analysis
  1.6.2 Market Drivers
  1.6.3 Market Restraints
  1.6.4 Market Opportunities

2. GLOBAL HEART FAILURE MARKET, BY DRUG CLASS, $MILLION, 2023-2035

2.1 Introduction
2.2 ACE Inhibitors
2.3 Beta Blockers
2.4 Diuretics
2.5 Angiotensin 2 Receptor Antagonist
2.6 Aldosterone Antagonist
2.7 Others

3. GLOBAL HEART FAILURE MARKET, BY REGION, $MILLION, 2023-2035

3.1 North America
  3.1.1 Key Findings
  3.1.2 Market Dynamics
  3.1.3 Market Sizing and Forecast
    3.1.3.1 North America Heart Failure Market (by Country)
      3.1.3.1.1 U.S.
      3.1.3.1.2 Canada
3.2 Europe
  3.2.1 Key Findings
  3.2.2 Market Dynamics
  3.2.3 Market Sizing and Forecast
    3.2.3.1 Europe Heart Failure Market (by Country)
      3.2.3.1.1 Germany
      3.2.3.1.2 France
      3.2.3.1.3 U.K.
      3.2.3.1.4 Italy
      3.2.3.1.5 Spain
      3.2.3.1.6 Rest-of-Europe
3.3 Asia-Pacific
  3.3.1 Key Findings
  3.3.2 Market Dynamics
  3.3.3 Market Sizing and Forecast
    3.3.3.1 Asia-Pacific Heart Failure Market (by Country)
      3.3.3.1.1 Japan
      3.3.3.1.2 China
      3.3.3.1.3 India
      3.3.3.1.4 Rest-of-Asia-Pacific
3.4 Rest-of-the World
  3.4.1 Key Findings
  3.4.2 Market Dynamics
  3.4.3 Market Sizing and Forecast

4. GLOBAL HEART FAILURE MARKET-COMPETITIVE BENCHMARKING AND COMPANY PROFILES

4.1 Competitive Landscape
  4.1.1 Key Strategies and Developments by Company
    4.1.1.1 Funding Activities
    4.1.1.2 Mergers and Acquisitions
    4.1.1.3 Regulatory Approvals
    4.1.1.4 Partnerships, Collaborations and Business Expansions
  4.1.2 Key Developments Analysis
4.2 Company Profiles
  4.2.1 Amgen Inc.
    4.2.1.1 Overview
    4.2.1.2 Product Portfolio
    4.2.1.3 Target Customers
    4.2.1.4 Key Personnels
    4.2.1.5 Analyst View
  4.2.2 Pfizer Inc.
    4.2.2.1 Overview
    4.2.2.2 Product Portfolio
    4.2.2.3 Target Customers
    4.2.2.4 Key Personnels
    4.2.2.5 Analyst View
  4.2.3 Novartis AG
    4.2.3.1 Overview
    4.2.3.2 Product Portfolio
    4.2.3.3 Target Customers
    4.2.3.4 Key Personnels
    4.2.3.5 Analyst View
  4.2.4 AstraZeneca Plc
    4.2.4.1 Overview
    4.2.4.2 Product Portfolio
    4.2.4.3 Target Customers
    4.2.4.4 Key Personnels
    4.2.4.5 Analyst View
  4.2.5 Merck & Co., Inc.
    4.2.5.1 Overview
    4.2.5.2 Product Portfolio
    4.2.5.3 Target Customers
    4.2.5.4 Key Personnels
    4.2.5.5 Analyst View
  4.2.6 Bristol-Myers Squibb (BMS)
    4.2.6.1 Overview
    4.2.6.2 Product Portfolio
    4.2.6.3 Target Customers
    4.2.6.4 Key Personnels
    4.2.6.5 Analyst View
  4.2.7 GlaxoSmithKline (GSK)
    4.2.7.1 Overview
    4.2.7.2 Product Portfolio
    4.2.7.3 Target Customers
    4.2.7.4 Key Personnels
    4.2.7.5 Analyst View
  4.2.8 Novo Nordisk
    4.2.8.1 Overview
    4.2.8.2 Product Portfolio
    4.2.8.3 Target Customers
    4.2.8.4 Key Personnels
    4.2.8.5 Analyst View
  4.2.9 Bayer AG
    4.2.9.1 Overview
    4.2.9.2 Product Portfolio
    4.2.9.3 Target Customers
    4.2.9.4 Key Personnels
    4.2.9.5 Analyst View

5. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure 1: Global Heart Failure Market Dynamics Impact Analysis
Figure 2: Global Heart Failure Market Coverage
Figure 3: Global Heart Failure Market Key Trends, Impact Analysis
Figure 4: Global Heart Failure Market, Competitive Landscape

List Of Tables

LIST OF TABLES

Table 1: Global Heart Failure Market, Comparative Analysis
Table 2: Global Heart Failure Market, Regulatory Scenario
Table 3: Global Heart Failure Market Dynamics, Impact Analysis
Table 4: Global Heart Failure Market (by Drug Class)